These require medical evaluation
Your prescriber says keep going as usual
Indian Generic GLP-1 Makers Cut Weight-Loss Drug Targets by 25-30% Last updated Jun 26, 2026 Patents for Novo Nordisk's GLP-1 drugs lapsed on March 20, letting dozens of Indian firms offer generics at 1,000-2,500 rupees monthly amid high obesity and diabetes rates
This move to an oral dose was made possible due to the advancement in bioavailability technology and is widely recognized as a breakthrough in the management of both type 2 diabetes and obesity
For a small but meaningful share of people, the experience falls short, not because the medication fails outright, but because the surrounding system does
Youll receive a new shipment each month and have access to their team for questions or dosage adjustments as needed